Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple MRI and blood test catch pancreatic cancer earlier?

NCT ID NCT07723781

Diagnosis Sponsor: Saskia Hendrich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This pilot study tests whether a structured case-finding pathway can help detect pancreatic cancer earlier in Swiss primary care. Adults aged 60 or older with warning signs like new-onset diabetes, unexplained weight loss, or a family history of pancreatic cancer are invited to undergo an MRI scan and a blood test for a biomarker called PancreaSure. The goal is to see if this approach is feasible and safe, paving the way for a larger national study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Structured case-finding pathway including MRI/MRCP and PancreaSure blood biomarker assay
What this could lead to
If successful, this approach could enable earlier detection of pancreatic cancer, potentially improving survival rates.
What could go wrong
This is a small pilot study focused on feasibility, not on proving the pathway works. The biomarker test is still exploratory, and false positives could lead to unnecessary procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 60 years or older with defined metabolic or familial/genetic risk factors for pancreatic ductal adenocarcinoma, recruited through GP practices in Canton Zurich and adjacent cantons, or via self-presentation through the study website (spot-cancer.ch).

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 60 years or older * Attendance at a participating GP practice in Canton Zurich or adjacent canton (maximum 1 hour travel time), or self-presentation via study microsite * At least one trigger criterion fulfilled: metabolic trigger (new-onset type 2 diabetes mellitus diagnosed within 24 months AND unintentional weight loss \>5% body weight within 3 months) OR familial/genetic trigger (≥2 first-degree relatives with PDAC, or ≥1 first-degree relative with PDAC, or BRCA1/2 germline mutation, or CDKN2A mutation); combined with age ≥60 years * Written informed consent * Sufficient German or English language skills for study communication Exclusion Criteria: * Prior or current diagnosis of pancreatic carcinoma or pre-malignant pancreatic lesion * Contraindication to MRI (metallic implants, severe claustrophobia without available alternative) * Active untreated psychiatric condition impairing capacity to consent * Pregnancy * Incapacity to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early detection of cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early detection of cancer Pancreatic adenocarcinoma (ductal adenocarcinoma)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Onkozentrum Zürich AG

    Zurich, Canton of Zurich, 8038, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.